| Literature DB >> 31341555 |
Kanidta Sooklert1, Asarn Wongjarupong2, Sarocha Cherdchom1, Nicha Wongjarupong3, Depicha Jindatip4, Yupa Phungnoi5, Rojrit Rojanathanes6, Amornpun Sereemaspun1.
Abstract
Silver nanoparticles (AgNPs) have been widely used in a variety of applications in innovative development; consequently, people are more exposed to this particle. Growing concern about toxicity from AgNP exposure has attracted greater attention, while questions about nanosilver-responsive genes and consequences for human health remain unanswered. By considering early detection and prevention of nanotoxicology at the genetic level, this study aimed to identify 1) changes in gene expression levels that could be potential indicators for AgNP toxicity and 2) morphological phenotypes correlating to toxicity of HepG2 cells. To detect possible nanosilver-responsive genes in xenogenic targeted organs, a comprehensive systematic literature review of changes in gene expression in HepG2 cells after AgNP exposure and in silico method, connection up- and down-regulation expression analysis of microarrays (CU-DREAM), were performed. In addition, cells were extracted and processed for transmission electron microscopy to examine ultrastructural alterations. From the Gene Expression Omnibus (GEO) Series database, we selected genes that were up- and down-regulated in AgNPs, but not up- and down-regulated in silver ion exposed cells, as nanosilver-responsive genes. HepG2 cells in the AgNP-treated group showed distinct ultrastructural alterations. Our results suggested potential representative gene data after AgNPs exposure provide insight into assessment and prediction of toxicity from nanosilver exposure.Entities:
Keywords: Silver nanoparticles; Silver-nanoparticle responsive gene; Systematic review; Ultrastructural alterations
Year: 2019 PMID: 31341555 PMCID: PMC6629447 DOI: 10.5487/TR.2019.35.3.257
Source DB: PubMed Journal: Toxicol Res ISSN: 1976-8257
Fig. 1Flow diagram illustrating systematic literature selection process in accordance with PRISMA guideline.
A systematic review of genotoxicity after AgNP exposure in HepG2 cells
| Study | AgNPs exposure in HepG2 cell line | Gene name | Gene symbol | Major outcome (fold change) | ||
|---|---|---|---|---|---|---|
|
| ||||||
| Particle size (nm) | Doses (μg/mL) | Exposure time (hr) | ||||
| Brzoska | 20, 200 | 100 | 2, 6, 24 | Fos proto-oncogene | Up-regulation (234.26) | |
| Early growth response 1 | Up-regulation (27.78) | |||||
| Selectin P ligand | Up-regulation (20.55) | |||||
| Jun proto-oncogene | Up-regulation (19.95) | |||||
| C-X-C motif chemokine ligand 8 | Up-regulation (18.05) | |||||
| Matrix metallopeptidase 10 | Up-regulation (15.70) | |||||
| WNT1 inducible signaling pathway protein 1 | Up-regulation (10.95) | |||||
| Growth arrest and DNA damage inducible alpha | Up-regulation (7.59) | |||||
| Heat shock protein family B (small) member 1 | Up-regulation (5.05) | |||||
| Interleukin 4 | Up-regulation (4.69) | |||||
| CCAAT/enhancer binding protein beta | Up-regulation (3.28) | |||||
| Vascular endothelial growth factor A | Up-regulation (2.86) | |||||
| C-C motif chemokine ligand 2 | Up-regulation (2.34) | |||||
| BCL2 related protein A1 | Up-regulation (2.16) | |||||
| Hexokinase 2 | Up-regulation (1.95) | |||||
| Cyclin dependent kinase inhibitor 1B | Down-regulation (2.16) | |||||
| Transferrin receptor | Down-regulation (2.09) | |||||
| Growth regulation by estrogen in breast cancer 1 | Down-regulation (1.61) | |||||
| Forkhead box A2 | FOXA2 | Down-regulation (1.52) | ||||
|
| ||||||
| Sahu | 20, 50 | 2.5 | 4, 24 | Metallothionein 1M | Up-regulation (5.71) | |
| Metallothionein 1B | Up-regulation (4.04) | |||||
| Metallothionein 1G | Up-regulation (3.36) | |||||
| Metallothionein 2A | Up-regulation (1.91) | |||||
| Metallothionein 1F | Up-regulation (1.89) | |||||
| SRY-box 4 | SOX4 | Up-regulation (1.80) | ||||
|
| ||||||
| Stepkowski | 20, 200 | 100 | 6 | Fos proto-oncogene | Up-regulation (247.39) | |
| Early growth response 1 | Up-regulation (26.38) | |||||
| Jun proto-oncogene | Up-regulation (24.34) | |||||
| Heme oxygenase 1 | Up-regulation (24.17) | |||||
| C-X-C motif chemokine ligand 8 | Up-regulation (18.08) | |||||
| Interleukin 10 | Up-regulation (5.59) | |||||
| Interferon beta 1 | Up-regulation (2.56) | |||||
| Mitogen-activated protein kinase kinase kinase 1 | Down-regulation (1.96) | |||||
| Tumor necrosis factor superfamily member 10 | Down-regulation (1.77) | |||||
| Receptor interacting serine/threonine kinase 1 | Down-regulation (1.74) | |||||
| Interleukin 1 receptor type 1 | Down-regulation (1.63) | |||||
|
| ||||||
| Jiao | 10, 100 | 0.2, 0.5, 1, 2 | 24 | Jun proto-oncogene | Up-regulation (2.3) | |
| Fos proto-oncogene | Up-regulation (2.1) | |||||
|
| ||||||
| Garcia-Reyero | 30 | 0.002–0.2 | 24 | Superoxide dismutase 3 | Up-regulation (13.18) | |
| Signal transducer and activator of transcription 1 | Up-regulation (3.55) | |||||
| Tumor protein p53 | Up-regulation (2.93) | |||||
| Signal transducer and activator of transcription 3 | Up-regulation (2.57) | |||||
| Flotillin 1 | Up-regulation (2.25) | |||||
| Hypoxia inducible factor 1 alpha subunit | HIF1A | Up-regulation (1.94) | ||||
|
| ||||||
| Kim | 10 | 0.2 | 24 | Catalase | Up-regulation (11.00) | |
| Superoxide dismutase 1 | SOD1 | Up-regulation (4.50) | ||||
|
| ||||||
| Kawata | 10 | 0.1–3 | 24 | Metallothionein 1H | Up-regulation (4.50) | |
| Metallothionein 2A | Up-regulation (4.10) | |||||
| Metallothionein 1X | Up-regulation (3.4) | |||||
| Heat shock protein family A (Hsp70) member 4 like | Up-regulation (2.2) | |||||
| Heat shock protein family B (small) member 1 | Up-regulation (2.1) | |||||
| Heat shock protein family H (Hsp110) member 1 | Up-regulation (2.1) | |||||
Indicates a gene which is present in multiple citations.
Characteristics of selected genes with significantly increased/decreased expression after AgNP exposure, based on a systematic review of HepG2 cells
| Subcellular location | Molecular function | Gene |
|---|---|---|
| Nucleus | Transcription factor | |
| Metal ion binding | ||
| ATP binding, Protein modification | ||
| Protein binding, Protein phosphate binding | ||
| Mitochondria | Hexokinase activity, ATP binding | HK2 |
| Metal ion binding (Intracellular antioxidant activity) | SOD1 | |
| Protein heterodimerization/homodimerization activity | BCL2A1 | |
| Endoplasmic reticulum | Heme oxygenase activity | HMOX1 |
| Peroxisome | Catalase activity, Antioxidant activity | CAT |
| Cytoplasm | Protein kinase binding | MAP3K1 |
| Cell membrane | Protein heterodimerization activity | FLOT1 |
| Transferrin transmembrane transporter activity | TFRC | |
| Metal ion biding, Receptor binding | TNFSF10 | |
| Receptor binding | SELPLG | |
| Death receptor binding, Protein serine/threonine kinase activity | RIPK1 | |
| Interleukin-1 receptor activity | IL1R1 | |
| Hormone-responsive tissues and cancer | GREB1 | |
| Extracellular space | Metal ion binding (Extracellular antioxidant activity) | SOD3 |
| Metalloendopeptidase activity, Metal ion binding | MMP10 | |
| Chemokine and cytokine activity | CXCL8, | |
| Vascular endothelial growth factor receptor binding | VEGFA | |
| Heparin binding, Integrin binding | WISP1 |
Indicates when a gene is down regulated by AgNPs.
Connection up- and down-regulation expression analysis of microarray (CU-DREAM) results. Gene intersections between HepG2 cells exposed to AgNPs with cysteine, astrong ionic silver ligand, and Ag ions
| Ag ion | AgNPs | ||
| Up ( | Not up | ||
| Up ( | 0 | 7 | |
| Not up | 18 | 8,187 | |
| 9.01E-01 | |||
| Ag ion | AgNPs | ||
| Down ( | Not down | ||
| Down ( | 7 | 16 | |
| Not down | 6 | 8,183 | |
| 7.35E-293 | |||
Characteristics of genes specifically up- and down-regulated by AgNP, but not Ag ions
| Subcellular location | Molecular function | Gene |
|---|---|---|
| Nucleus | Transcription factor | CEBPA, MYBL2, CD3EAP, SUV39H1, SOX15, MAFF |
| Nucleus, Cytoplasm | ATP binding | CKB, RECQL4 |
| GTPase activator activity | RGS10 | |
| Cytoplasm | ATP binding | XYLB |
| ATP binding, Protein kinase activity | MAP2K2 | |
| Protein homodimerization activity | FASN | |
| Cadherin binding | TAGLN2 | |
| Protease binding, Structural molecule activity | CSTA | |
| Cell membrane | ATPase coupled ion transmembrane transporter activity | ATP6V0E2 |
| ATPase activator activity | RAB3A | |
| Nucleoside transmembrane transporter activity | SLC29A1 | |
| Extracellular space | Erythropoietin receptor binding, Hormone activity | EPO |
| Growth factor and cytokine activity | BMP6 | |
| Enzyme inhibitor activity | SCG5 | |
| Chemokine activity | CCL20 | |
| Calcium ion binding, Metalloendopeptidase activity | TLL1 | |
| Carbohydrate binding, Growth factor activity | REG1A | |
| Cytoskeleton | Cadherin binding, Structural molecule activity | EVPL |
Indicates when a gene is down regulated by AgNPs.
Fig. 2Characterization of AgNPs. (A) UV-Vis spectrum of AgNPs. (B) Representative TEM image of AgNPs (scale bar: 50 nm).
Fig. 3Effect of AgNPs on the viability of HepG2 cells at 24 hr. (A) A dose dependent decrease in percentage of viable cells following AgNPs exposure. (B) Percentage of viable cells following AgNPs and Ag ions exposure. Data are the average of five replicate samples (*p< 0.01 compared with the Ag ions-treated group, **p< 0.001 compared with the control group).
Fig. 4Morphological death patterns of cells treated with AgNPs. Transmission electron image of HepG2 cells incubated for 24 hr with (A) 0.5 μg/mL AgNPs, (B) 2 μg/mL AgNPs or (C) 6 μg/mL AgNPs.
Fig. 5AgNPs induced the changes in the ultrastructural morphology of cytoplasmic organelles. Cells were treated with (A) control, (B–F) AgNPs (6 μg/mL) for 24 hr and processed for TEM. Notes: Representative TEM micrograph of AgNP-treated cells showed (B) nuclear membrane distortion (black arrow) and numerous initial autophagic vacuoles (Avi), (C) internalization of aggregated-AgNPs in cytosolic vesicles (black stars) and swollen lipid droplets (white stars), (D) blebbed nuclei (black arrow) and accumulation of both initial autophagic vacuoles (inset) and degradative autophagic vacuoles (Avd), (E) swollen mitochondria and mitochondrial cristae disappear (double arrows), and (F) dilation of Golgi saccules (white arrow).
Fig. 6Death pattern analysis of cells treated with AgNPs. (A) Representative histograms from flow cytometry of HepG2 cells treated with different concentrations of AgNPs. (B) Distribution of viable, apoptotic, and necrotic cells treated with different concentrations of AgNPs as measured by annexin V and PI staining.
Fig. 7AgNPs induce autophagy in HepG2 cells. (A) Western blot analysis of autophagy related proteins (LC3) in HepG2 cells treated with a series of concentrations of AgNPs. (B) Quantification of the LC3-II/β-actin ratio (**p< 0.001 and ***p< 0.0001 compared with the control group).